Teplizumab improves and stabilizes beta cell function in antibody-positive high-risk individuals
Emily K. Sims, Brian N. Bundy, Kenneth Stier, Elisavet Serti, Noha Lim, S. Alice Long, Susan Geyer, Antoinette Moran, Carla J. Greenbaum, Carmella Evans‐Molina, Kevan C. Herold, Type 1 Diabetes TrialNet Study Group, Linda A. DiMeglio, Stephen E. Gitelman, Peter A. Gottlieb, Jennifer B. Marks, Wayne D. Moore, Henry Rodriguez, William E. Russell, Desmond Schatz, Eva Tsalikian, Diane K. Wherrett, Anette‐Gabriele Ziegler
Abstract
T cell subsets indicated that partially exhausted effector cells were associated with clinical response. Thus, this trial showed improvement in metabolic responses and delay of diabetes with immune therapy.
Topics & Concepts
BETA (programming language)CD8AntibodyFunction (biology)CellMedicineCell biologyChemistryInternal medicineImmunologyBiologyImmune systemBiochemistryComputer scienceProgramming languageDiabetes and associated disordersDiabetes Management and ResearchPancreatic function and diabetes